Aura Biosciences reports 2025 net loss $106.2M; Phase 3 CoMpass enrollment to complete mid-2026

Aura Biosciences, Inc.

Cash and equivalents $144.2M as of Dec 31, 2025; sufficient to fund operations into Q1 2027.
Phase 3 CoMpass trial enrollment completion expected by mid-2026; topline data in 2H 2027.
Phase 1b/2 NMIBC trial initial 3-month clinical data on track for mid-2026.
New formulation for non-ocular solid tumors achieved 12-month stability; patent filed for coverage into 2046.
Net loss for 2025 was $106.2M vs $86.9M in 2024; R&D expenses increased to $90.3M.

item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Aura Biosciences, Inc. reported financial results for the fourth quarter and year ended December 31, 2025.

Period: the fourth quarter and year ended December 31, 2025
Result: reported results

Exact text from the filing

Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today reported financial results for the fourth quarter and year ended December 31, 2025, and provided recent business highlights.

View on SEC.gov

1349 earnings releases filed in the last 30 days. Browse all earnings releases →

Aura Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-130383

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.